logo
Plus   Neg
Share
Email

Insmed Inc. (INSM) Is Up After Release Of Additional Study Results

Insmed Inc. (INSM) announced after the close Wednesday that it has released additional data from its Phase 3 clinical program for adult patients with treatment refractory NTM lung disease.

"The interim results announced today from our ongoing INS-212 and INS-312 studies provide confirmation of the initial positive clinical data released in September 2017. These data validate the initial and continued treatment effect of ALIS in combination with GBT and also demonstrate the durability of this effect in this challenging patient population," stated Chief Medical Officer Dr. Paul Streck.

Insmed climbed during the first 45 minutes of trade Wednesday, but was range-bound for the remainder of the session. The stock closed up by 0.53 at $32.99. Insmed is now up 1.51 on 39K shares after the bell

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

RELATED NEWS
Trade INSM now with 
Follow RTT